LIVIVO - Search results -

Search results

Result 1 - 10 of total 55

Search options

Article ; Online: Cost Variation in Temporizing External Fixation of Tibial Plateau Fractures.

Hayek, Kevin R / Parikh, Harsh R / McCreary, Dylan L / Westberg, Jerald R / Mirick, Gudrun / Baynard, Taurean / Schmidt, Andrew H / Cunningham, Brian P

Journal of orthopaedic trauma

2019 Volume 33 Suppl 7, Page(s) S5–S10

Abstract: ... noted between construct cost and patient demographics (r = 0.02), fracture characteristics (r = 0.02 ... or injury-independent characteristics (r = 0.10). Finally, there was no significant difference ...

Abstract	Background: Rising health care expenditures and declining reimbursements have generated interest in providing interventions of value. The use of external fixation is a commonly used intermediate procedure for the staged treatment of unstable fractures. External fixator constructs can vary in design and costs based on selected component configuration. The objective of this study was to evaluate cost variation and relationships to injury and noninjury characteristics in temporizing external fixation of tibial plateau fractures. We hypothesize that construct costs are highly variable and present no noticeable patterns with both injury and noninjury characteristics. Methods: A retrospective review of tibial plateau fractures treated with initial temporizing external fixation between 2010 and 2016 at 2 Level I trauma centers was conducted. Fracture and patient characteristics including age, body mass index, AO/OTA classification, and Schatzker fracture classification were observed with construct cost. In addition, injury-independent characteristics of surgeon education, site of procedure, and date of procedure were evaluated with construct cost. Factors associated with cost variation were assessed using nonparametric comparative and goodness-of-fit regression tests. Results: Two hundred twenty-one patient cases were reviewed. The mean knee spanning fixator construct cost was $4947 (95% confidence interval = $4742-$5152). The overall range in construct costs was from $1848 to $11,568. The mean duration of use was 16.4 days. No strong correlations were noted between construct cost and patient demographics (r = 0.02), fracture characteristics (r = 0.02), or injury-independent characteristics (r = 0.10). Finally, there was no significant difference between constructs of traumatologists and other orthopaedic surgeon subspecialists (P = 0.12). Conclusions: Temporizing external fixation of tibial plateau is a high-cost intervention per unit of time and exhibits massive variation in the mean cost. This presents an ideal opportunity for cost savings by reducing excessive variation in implant component selection. Level of evidence: Level III. Retrospective Cohort.
MeSH term(s)	Cost Savings ; External Fixators/economics ; Fracture Fixation/economics ; Fracture Fixation/instrumentation ; Health Care Costs ; Humans ; Retrospective Studies ; Tibial Fractures/economics ; Tibial Fractures/etiology ; Tibial Fractures/surgery ; Trauma Centers
Language	English
Publishing date	2019-10-18
Publishing country	United States
Document type	Journal Article
ZDB-ID	639099-7
ISSN	1531-2291 ; 0890-5339
ISSN (online)	1531-2291
ISSN	0890-5339
DOI	10.1097/BOT.0000000000001620
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2234: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Systemic versus free antibiotic delivery in preventing acute exogenous implant related infection in a rat model.

Marston, Scott / Mirick Mueller, Gudrun / Sabin, Arick / Hansen, Glen T / Lindgren, Bruce / Aparicio, Conrado / Armstrong, Alexandra R / Larsen, Ole H / Schmidt, Andrew / Kyle, Richard / Gustilo, Ramon / Tsukayama, Dean / Bechtold, Joan / Bue, Mats

Journal of orthopaedic research : official publication of the Orthopaedic Research Society

2021 Volume 40, Issue 2, Page(s) 429–438

Abstract: We studied systemic ceftriaxone, and free/local tobramycin and doxycycline in a controlled rat model representing a generic acute exogenous joint infection. We hypothesized that evidence of infection (quantitative colony forming units [CFU], qualitative ... ...

Abstract	We studied systemic ceftriaxone, and free/local tobramycin and doxycycline in a controlled rat model representing a generic acute exogenous joint infection. We hypothesized that evidence of infection (quantitative colony forming units [CFU], qualitative scanning electron microscopy [SEM], histopathology) (1a) would be reduced with local versus systemic antibiotic, (1b) any antibiotic would be superior to control, (2) there would be a difference among antibiotics, and (3) antibiotic would not be detectable in serum at 4-week euthanasia. Study groups included infected and noninfected (1) control (no treatment), (2) systemic ceftriaxone (daily), (3) local tobramycin, and (4) local doxycycline (10 rats/group; power = 0.8). With IACUC approval, a reliable acute exogenous joint infection was created by slowly injecting 50-μl, 10
MeSH term(s)	Animals ; Anti-Bacterial Agents ; Ceftriaxone ; Doxycycline ; Prosthesis-Related Infections/drug therapy ; Prosthesis-Related Infections/prevention & control ; Rats ; Rats, Sprague-Dawley ; Staphylococcal Infections/drug therapy ; Staphylococcal Infections/prevention & control ; Tobramycin
Chemical Substances	Anti-Bacterial Agents ; Ceftriaxone (75J73V1629) ; Doxycycline (N12000U13O) ; Tobramycin (VZ8RRZ51VK)
Language	English
Publishing date	2021-05-03
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	605542-4
ISSN	1554-527X ; 0736-0266
ISSN (online)	1554-527X
ISSN	0736-0266
DOI	10.1002/jor.25052
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1879: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Acute Lower Extremity Fracture Management in Chronic Spinal Cord Injury: 2022 Delphi Consensus Recommendations.

Carbone, L D / Ahn, J / Adler, R A / Cervinka, T / Craven, C / Geerts, W / Hsu, J R / Huang, D / Karunakar, M A / Kiratli, B J / Krause, P C / Morse, L R / Mirick Mueller, G E / Nana, A / Rogers, E / Rivera, J C / Spitler, C / Weaver, F M / Obremskey, W

JB & JS open access

2022 Volume 7, Issue 4

Abstract: Our objective was to develop a clinical practice guideline (CPG) for the treatment of acute lower extremity fractures in persons with a chronic spinal cord injury (SCI).: Methods: Information from a previous systematic review that addressed lower ... ...

Abstract	Our objective was to develop a clinical practice guideline (CPG) for the treatment of acute lower extremity fractures in persons with a chronic spinal cord injury (SCI). Methods: Information from a previous systematic review that addressed lower extremity fracture care in persons with an SCI as well as information from interviews of physical and occupational therapists, searches of the literature, and expert opinion were used to develop this CPG. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system was used to determine the quality of evidence and the strength of the recommendations. An overall GRADE quality rating was applied to the evidence. Conclusions: Individuals with a chronic SCI who sustain an acute lower extremity fracture should be provided with education regarding the risks and benefits of operative and nonoperative management, and shared decision-making for acute fracture management should be used. Nonoperative management historically has been the default preference; however, with the advent of greater patient independence, improved surgical techniques, and advanced therapeutics and rehabilitation, increased use of surgical management should be considered. Physical therapists, kinesiotherapists, and/or occupational therapists should assess equipment needs, skills training, and caregiver assistance due to changes in mobility resulting from a lower extremity fracture. Therapists should be involved in fracture management as soon as possible following fracture identification. Pressure injuries, compartment syndrome, heterotopic ossification, nonunion, malunion, thromboembolism, pain, and autonomic dysreflexia are fracture-related complications that clinicians caring for patients who have an SCI and a lower extremity fracture may encounter. Strategies for their treatment are discussed. The underlying goal is to return the patient as closely as possible to their pre-fracture functional level with operative or nonoperative management.
Language	English
Publishing date	2022-12-08
Publishing country	United States
Document type	Journal Article
ISSN	2472-7245
ISSN (online)	2472-7245
DOI	10.2106/JBJS.OA.21.00152
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Intensity dependence of two-wave mixing absorption in a resonant medium.

He, G S / Mirick, J W / Chang, R S / Djeu, N

Optics letters

2008 Volume 12, Issue 8, Page(s) 582–584

Abstract: Two-wave mixing absorption in a supersonic beam containing I2 has been studied. The results are in agreement with theory for probe intensities comparable with the pump intensity. However, at very low probe-beam intensities, the absorption deviates ... ...

Abstract	Two-wave mixing absorption in a supersonic beam containing I2 has been studied. The results are in agreement with theory for probe intensities comparable with the pump intensity. However, at very low probe-beam intensities, the absorption deviates substantially from the predicted value and becomes the same as that for the pump beam alone. We believe that this behavior is caused by density variations in the molecular beam and suggest that this effect can be developed into a tool for probing optical inhomogeneities on a microscopic scale.
Language	English
Publishing date	2008-09-11
Publishing country	United States
Document type	Journal Article
ISSN	0146-9592
ISSN	0146-9592
DOI	10.1364/ol.12.000582
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words.

Mirick, G R / Bradt, B M / Denardo, S J / Denardo, G L

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

2004 Volume 48, Issue 4, Page(s) 251–257

Abstract: The United States Food and Drug Administration (FDA) has approved unconjugated monoclonal antibodies (MAbs) for immunotherapy (IT) of B-cell lymphoma, breast cancer and acute myeloid leukemia. More recently, approval has been given for conjugated ... ...

Abstract	The United States Food and Drug Administration (FDA) has approved unconjugated monoclonal antibodies (MAbs) for immunotherapy (IT) of B-cell lymphoma, breast cancer and acute myeloid leukemia. More recently, approval has been given for conjugated ZevalinTM ((90)yttrium ibritumomab tiuxetan, IDEC-Y2B8, Biogen Idec, Cambridge, MA) and BexxarTM ((131)I-tositumomab, Corixa, Corp., Seattle, WA and GlaxoSmithKline, Philadelphia, PA) anti-CD20 MAbs for use in radioimmunotherapy (RIT) of non-Hodgkin's lymphoma (NHL), thus redefining the standard care of cancer patients. Because of, and despite a lack of basis for concern about allergic reactions due to human antibody responses to these foreign proteins, assays were developed to determine HAGA (human anti-globulin antibody) levels that developed in patient sera following treatment with MAbs. Strategies were also devised to ''humanize'' MAbs and to temporarily block patient immune function with drugs in order to decrease the seroconversion rates, with considerable success. On the other hand, a survival advantage has been observed in some patients who developed a HAGA following treatment. This correlates with development of an anti-idiotype antibody cascade directed toward the MAbs used to treat these patients. What follows is a selective review of HAGA and its effect on cancer treatment over the past 2 decades.
MeSH term(s)	Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/immunology ; Antibodies, Neoplasm/immunology ; Antigen-Antibody Reactions/immunology ; Humans ; Neoplasms/immunology ; Neoplasms/radiotherapy ; Radioimmunotherapy/adverse effects ; Radioimmunotherapy/methods ; Serum Globulins/immunology
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Neoplasm ; Serum Globulins
Language	English
Publishing date	2004-12
Publishing country	Italy
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S. ; Review
ZDB-ID	1281687-5
ISSN	1827-1936 ; 1824-4785 ; 0392-0208 ; 1125-0135 ; 1824-4661
ISSN (online)	1827-1936
ISSN	1824-4785 ; 0392-0208 ; 1125-0135 ; 1824-4661
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Night shift work, light at night, and risk of breast cancer.

Davis, S / Mirick, D K / Stevens, R G

Journal of the National Cancer Institute

2001 Volume 93, Issue 20, Page(s) 1557–1562

Abstract: Background: Exposure to light at night may increase the risk of breast cancer by suppressing the normal nocturnal production of melatonin by the pineal gland, which, in turn, could increase the release of estrogen by the ovaries. This study investigated ...

Abstract	Background: Exposure to light at night may increase the risk of breast cancer by suppressing the normal nocturnal production of melatonin by the pineal gland, which, in turn, could increase the release of estrogen by the ovaries. This study investigated whether such exposure is associated with an increased risk of breast cancer in women. Methods: Case patients (n = 813), aged 20-74 years, were diagnosed from November 1992 through March 1995; control subjects (n = 793) were identified by random-digit dialing and were frequency matched according to 5-year age groups. An in-person interview was used to gather information on sleep habits and bedroom lighting environment in the 10 years before diagnosis and lifetime occupational history. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by use of conditional logistic regression, with adjustment for other potential risk factors. Results: Breast cancer risk was increased among subjects who frequently did not sleep during the period of the night when melatonin levels are typically at their highest (OR = 1.14 for each night per week; 95% CI = 1.01 to 1.28). Risk did not increase with interrupted sleep accompanied by turning on a light. There was an indication of increased risk among subjects with the brightest bedrooms. Graveyard shiftwork was associated with increased breast cancer risk (OR = 1.6; 95% CI = 1.0 to 2.5), with a trend of increased risk with increasing years and with more hours per week of graveyard shiftwork (P =.02, Wald chi-squared test). Conclusion: The results of this study provide evidence that indicators of exposure to light at night may be associated with the risk of developing breast cancer.
MeSH term(s)	Adult ; Aged ; Breast Neoplasms/epidemiology ; Breast Neoplasms/etiology ; Circadian Rhythm/radiation effects ; Electromagnetic Fields ; Environmental Exposure ; Female ; Habits ; Humans ; Light/adverse effects ; Lighting ; Melatonin/metabolism ; Melatonin/pharmacology ; Middle Aged ; Occupational Exposure ; Occupations ; Pineal Gland/metabolism ; Pineal Gland/radiation effects ; Residence Characteristics ; Risk Factors ; Secretory Rate/radiation effects ; Sleep ; Work Schedule Tolerance
Chemical Substances	Melatonin (JL5DK93RCL)
Language	English
Publishing date	2001-10-17
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	2992-0
ISSN	1460-2105 ; 0027-8874 ; 0198-0157
ISSN (online)	1460-2105
ISSN	0027-8874 ; 0198-0157
DOI	10.1093/jnci/93.20.1557
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.131: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia.

DeNardo, G L / Mirick, G R / Hok, S / DeNardo, S J / Beckett, L A / Adamson, G N / Balhorn, R L

International journal of oncology

2009 Volume 34, Issue 2, Page(s) 511–516

Abstract: Like rituximab, monoclonal antibodies reactive with human leukocyte antigen have potent antilymphoma activity. However, size limits their vascular and tissue penetration. To mimic monoclonal antibody binding, nanomolecules have been synthesized, shown ... ...

Abstract	Like rituximab, monoclonal antibodies reactive with human leukocyte antigen have potent antilymphoma activity. However, size limits their vascular and tissue penetration. To mimic monoclonal antibody binding, nanomolecules have been synthesized, shown specific for the beta subunit of HLA-DR10, and selective for cells expressing this protein. Selective high affinity ligands (SHALs) containing the 3-(2-([3-chloro-5-trifluoromethyl)-2-pyridinyl]oxy)-anilino)-3-oxopropanionic acid (Ct) ligand residualized and had antilymphoma activity against expressing cells. Herein, we show the extraordinary potency in mice with human lymphoma xenografts of a tridentate SHAL containing this ligand. After titrating antilymphoma activity in cell culture, a randomized preclinical study of a tridentate SHAL containing the Ct ligand was conducted in mice with established and aggressive human lymphoma xenografts. Mice having HLA-DR10 expressing Raji B- or Jurkat's T-lymphoma xenografts were randomly assigned to receive either treatment with SHAL at a dose of 100 ng i.p. weekly for 3 consecutive weeks, or to be untreated. Primary end-points were cure, overall response rates and survival. Toxicity was also evaluated in these mice, and a USFDA general safety study was conducted in healthy Balb/c mice. In Raji cell culture, the threshold and IC50 concentrations for cytotoxic activity were 0.7 and 2.5 nmol (pm/ml media), respectively. When compared to treated Jurkat's xenografts or untreated xenografts, Raji xenografts treated with the SHAL showed an 85% reduction in hazard of death (P=0.014; 95% confidence interval 32-95% reduction). There was no evidence for toxicity even after i.p. doses 2000 times greater than the treatment dose associated with cure of a majority of the mice with Raji xenografts. When compared with control groups, treatment selectively improved response rates and survival in mice with HLA-DR10 expressing human lymphoma xenografts at doses not associated with adverse events and readily achievable in patients.
MeSH term(s)	Animals ; Cell Line, Tumor/pathology ; Cell Line, Tumor/transplantation ; Cell Survival ; HLA-DR Antigens/immunology ; Humans ; Immunoglobulins/immunology ; Jurkat Cells ; Leukemia/drug therapy ; Leukemia/immunology ; Leukemia/mortality ; Leukemia/pathology ; Lymphoma/drug therapy ; Lymphoma/immunology ; Lymphoma/mortality ; Lymphoma/pathology ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Neoplasm Transplantation ; Survival Analysis ; Transplantation, Heterologous
Chemical Substances	HLA-DR Antigens ; Immunoglobulins
Language	English
Publishing date	2009-01-16
Publishing country	Greece
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	1154403-x
ISSN	1019-6439
ISSN	1019-6439
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3690: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Development of TNKase-specific cleavable peptide-linked radioimmunoconjugates for radioimmunotherapy.

Natarajan, Arutselvan / Kumaresan, Pappanaicken R / Denardo, Sally J / Denardo, Gerald L / Mirick, Gary / Lam, Kit S

Bioorganic & medicinal chemistry letters

2008 Volume 18, Issue 17, Page(s) 4802–4805

Abstract: Radioimmunotherapy (RIT) is a method for selectively delivering radionuclides to cancer cells while reducing the radiation dose to normal tissues. However, because of slow clearance of MAbs, normal tissues also received radiotoxicity. One of the ... ...

Abstract	Radioimmunotherapy (RIT) is a method for selectively delivering radionuclides to cancer cells while reducing the radiation dose to normal tissues. However, because of slow clearance of MAbs, normal tissues also received radiotoxicity. One of the promising strategies is linking on-demand cleavable (ODC) peptides between radiometal chelates and the tumor targeting agents. We have tested this proof-of-concept by using ODC peptides that are designed to be cleaved only by TNKase and are resistant to cleavage by enzymes present in the plasma and the tumor. TNKase-specific peptide linkers using l- and d-amino acids were screened by OBOC combinatorial peptide libraries. One of the best peptides was linked to radiometal chelate and ChL6-MAb to prepare radioimmunoconjugate (RIC). Optimization and characterization of the linker conjugation to MAb show (a) 1-2 peptides linked to each MAb; (b) immunoreactivity >80%; (c) specific activity of the RIC 0.7-1 microCi/microg; (d) RIC stable over 7 days in human plasma; and (e) radiometal-chelated ODC peptide cleaved from the RIC in plasma by TNKase at clinical dose levels of 10 microg/ml. The percent release of radiochelate from RIC was 50% at 24h and 85% over 7 2h in vitro. This novel ODC-linked RIC could be a potential molecule for RIT.
MeSH term(s)	Animals ; Antibodies, Monoclonal/metabolism ; Antibodies, Monoclonal/therapeutic use ; Humans ; Hydrolysis ; Immunoconjugates/therapeutic use ; Mice ; Neoplasms/immunology ; Neoplasms/metabolism ; Neoplasms/radiotherapy ; Peptides/chemistry ; Peptides/metabolism ; Peptides/therapeutic use ; Radioimmunotherapy/methods ; Tissue Plasminogen Activator/metabolism ; Tissue Plasminogen Activator/therapeutic use ; Tumor Cells, Cultured
Chemical Substances	Antibodies, Monoclonal ; ChL6 monoclonal antibody ; Immunoconjugates ; Peptides ; Tissue Plasminogen Activator (EC 3.4.21.68) ; tenecteplase (WGD229O42W)
Language	English
Publishing date	2008-09-01
Publishing country	England
Document type	Comparative Study ; Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	1063195-1
ISSN	1464-3405 ; 0960-894X
ISSN (online)	1464-3405
ISSN	0960-894X
DOI	10.1016/j.bmcl.2008.07.097
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3203: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics.

Natarajan, A / Gruettner, C / Ivkov, R / DeNardo, G L / Mirick, G / Yuan, A / Foreman, A / DeNardo, S J

Bioconjugate chemistry

2008 Volume 19, Issue 6, Page(s) 1211–1218

Abstract: ... microCi/2.2 mg and 6-11 microg of mAb/2.2 mg of NP. Mean tumor uptakes (% ID/g +/- SD) of each SPIO 20 nm ...

Abstract	Dextran and PEG-coated iron oxide nanoparticles (NP), when suitably modified to enable conjugation with molecular targeting agents, provide opportunities to target cancer cells. Monoclonal antibodies, scFv, and peptides conjugated to 20 nm NP have been reported to target cancer for imaging and alternating magnetic field (AMF) therapy. The physical characteristics of NPs can affect their in vivo performance. Surface morphology, surface charge density, and particle size are considered important factors that determine pharmacokinetics, toxicity, and biodistribution. New NanoFerrite (NF) particles having improved specific AMF absorption rates and diameters of 30 and 100 nm were studied to evaluate the variation in their in vitro and in vivo characteristics in comparison to the previously studied 20 nm superparamagnetic iron oxide (SPIO) NP. SPIO NP 20 nm and NF NP 30 and 100 nm were conjugated to (111)In-DOTA-ChL6, a radioimmunoconjugate. Radioimmunoconjugates were conjugated to NPs using 25 microg of RIC/mg of NP by carbodiimide chemistry. The radioimmunonanoparticles (RINP) were purified and characterized by PAGE, cellulose acetate electrophoresis (CAE), live cell binding assays, and pharmacokinetics in athymic mice bearing human breast cancer (HBT 3477) xenografts. RINP (2.2 mg) were injected iv and whole body; blood and tissue data were collected at 4, 24, and 48 h. The preparations used for animal study were >90% monomeric by PAGE and CAE. The immunoreactivity of the RINP was 40-60% compared to (111)In-ChL6. Specific activities of the doses were 20-25 microCi/2.2 mg and 6-11 microg of mAb/2.2 mg of NP. Mean tumor uptakes (% ID/g +/- SD) of each SPIO 20 nm, NF 30 nm, and 100 nm RINP at 48 h were 9.00 +/- 0.8 (20 nm), 3.0 +/- 0.3 (30 nm), and 4.5 +/- 0.8 (100 nm), respectively; the ranges of tissue uptakes were liver (16-32 +/- 1-8), kidney (7.0-15 +/- 1), spleen (8-17 +/- 3-8), lymph nodes 5-6 +/- 1-2), and lung (2.0-4 +/- 0.1-2). In conclusion, this study demonstrated that 100 nm NF NP could be conjugated to (111)In-mAb so that the resulting RINP had characteristics suitable for AMF therapy. Although 100 nm RINP targeted tumor less than 20 nm SPIO RINP, their heating capacity is typically 6 times greater, suggesting the 100 nm NF RINP could still deliver better therapy with AMF.
MeSH term(s)	Animals ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/metabolism ; Cell Line, Tumor ; Female ; Ferric Compounds/chemistry ; Hot Temperature/therapeutic use ; Humans ; Immunoconjugates/chemistry ; Immunoconjugates/metabolism ; Immunoconjugates/pharmacokinetics ; Indium Radioisotopes ; Magnetics ; Mice ; Nanoparticles/chemistry ; Particle Size ; Photons ; Polyethylene Glycols/chemistry ; Radioimmunoassay ; Spectrum Analysis ; Tissue Distribution
Chemical Substances	Antibodies, Monoclonal ; Ferric Compounds ; Immunoconjugates ; Indium Radioisotopes ; ferrite (1317-54-0) ; ferric oxide (1K09F3G675) ; Polyethylene Glycols (3WJQ0SDW1A)
Language	English
Publishing date	2008-06-03
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	1024041-x
ISSN	1520-4812 ; 1043-1802
ISSN (online)	1520-4812
ISSN	1043-1802
DOI	10.1021/bc800015n
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3400: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: A comparison of the efficacy of chloramphenicol (chloromycetin) and of penicillin in the treatment of pneumococcal lobar pneumonia.

AUSTRIAN, R / CLUFF, L E / MIRICK, G S / SESSOMS, S M / ZUBROD, C G

Bulletin of the Johns Hopkins Hospital

2003 Volume 91, Issue 5, Page(s) 323–329

MeSH term(s)	Chloramphenicol/therapeutic use ; Humans ; Penicillins/therapeutic use ; Pneumonia/therapy ; Pneumonia, Pneumococcal/therapy
Chemical Substances	Penicillins ; Chloramphenicol (66974FR9Q1)
Language	English
Publishing date	2003-09-16
Publishing country	United States
Document type	Journal Article
ZDB-ID	218291-9
ISSN	0097-1383
ISSN	0097-1383
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.101/A: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito